BEGESAND
DEAD

Serial Number

79201532

Owner

ADIENNE SA

Attorney

Monica Riva Talley

Filing Date

Sep 8, 2016

Add to watchlist:

No watchlists yet
View on USPTO

BEGESAND Trademark

Serial Number: 79201532 • Registration: 5372122

BEGESAND is a trademark filed by ADIENNE SA on September 8, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

ADIENNE SA (4 trademarks)

Via Zurigo, 46

Entity Type: 98

Trademark Details

Filing Date

September 8, 2016

Registration Date

January 9, 2018

Published for Opposition

October 24, 2017

Cancellation Date

July 26, 2024

Goods & Services

Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; medical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; and veterinary preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; sanitary preparations for medical purposes; dietetic food for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, and substances in the nature of beverages for medical or veterinary use; monoclonal antibodies and antibody mixtures for medical use, namely, diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing; monoclonal antibodies for immunomodulatory treatments, in particular for the treatment of diseases mediated by the differentiation cluster 26 molecule CD26; pharmaceutical preparations comprising as active ingredient monoclonal antibodies having immunomodulatory effects, in particular for the treatment of diseases mediated by the 26 differentiation cluster molecule CD26; dietetic foods, namely, yogurt and rice-derived products, namely, rice flour adapted for medical use, dietetic beverages adapted for medical use, food supplements, enzyme food supplements, protein food supplements, protein supplements for animals, by-products of the processing of cereals for dietetic or medical use, biological preparations for medical use, biological preparations for veterinary use, pills for medicines, namely, immunosuppressant pills, chemical preparations for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, chemical preparations for veterinary use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, biological tissue cultures for medical use, biological tissue cultures for veterinary use, enzyme preparations for medical use, enzyme preparations for veterinary use, enzymes for medical use, enzymes for veterinary use, medicines for veterinary use for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for veterinary use, namely, monoclonal antibodies for immunomodulatory treatments, vaccines, veterinary products in the nature of anti-infective products for veterinary use; living tissue grafts, surgical implants composed of living tissue, radiological contrast substances for medical use, diagnostic preparations for medical use, biomarker reagents for diagnosis for medical use, adjuvants for medical use, chemical preparations for pharmaceutical use, drugs for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations, namely, elixirs for treating viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, plant extracts for pharmaceutical use, medicinal infusions for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, lotions for pharmaceutical use, medicines or human medicine for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for human medicine in the nature of solution for injection for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations for skin care, pharmaceutical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, syrups for pharmaceutical use for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders

Surgical, medical, dental and veterinary apparatus and instruments, namely, infusion bag, vial, syringe; needles for medical use, medical apparatus and instruments, containers for applying medicines, namely, infusion bag, vial, syringe, hypodermic syringes, syringes for medical use, pumps for medical use, namely, infusion pump

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Jul 11, 2025 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jun 24, 2025 INTS
INVALIDATION PROCESSED
Jun 24, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 26, 2025 INTR
CANCELLED SECTION 71
Jul 26, 2024 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 9, 2023 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Dec 31, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 1, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 16, 2018 FICS
FINAL DISPOSITION PROCESSED
Apr 16, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 9, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 9, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 24, 2017 NPUB
PUBLISHED FOR OPPOSITION
Oct 24, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Oct 21, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 4, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 4, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 4, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2017 CRFA
ASSIGNED TO LIE
Aug 23, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 2, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 24, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 24, 2017 REAP
REFUSAL PROCESSED BY IB
Mar 18, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 28, 2017 RFCS
REFUSAL PROCESSED BY MPU
Feb 28, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 25, 2017 RFCR
NON-FINAL ACTION WRITTEN
Feb 24, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 21, 2017 MAFR
ASSIGNED TO EXAMINER
Feb 17, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 17, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 16, 2017 REPR